|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 65.96 USD | +2.14% |
|
+1.82% | -18.58% |
| May. 09 | Declaration of Voting Results by Gilead Sciences | CI |
| May. 09 | Declaration of Voting Results by Gilead Sciences | CI |
April 25 (Reuters) - The U.S. Food and Drug Administration on Monday granted approval for Gilead Sciences Inc's COVID-19 drug remdesivir to treat infants and children over 28 days of age.
The FDA's decision makes the drug the first approved COVID-19 treatment for children less than 12 years of age, the agency said. (Reporting by Manas Mishra in Bengaluru; Editing by Aditya Soni)
| 1st Jan change | Capi. | |
|---|---|---|
| -18.58% | 82.18B | |
| +30.38% | 684B | |
| +26.51% | 568B | |
| -4.36% | 361B | |
| +19.30% | 329B | |
| +3.73% | 284B | |
| +16.70% | 240B | |
| +8.78% | 208B | |
| -7.93% | 200B | |
| +7.68% | 166B |
GILEAD SCIENCES, INC. 
